Logotype for Techstep

Techstep (TECH) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Techstep

Q3 2026 earnings summary

11 Nov, 2026

Executive summary

  • Q3 revenue and net gross profit declined amid the BCM divestment, legacy Telecom Expense discontinuation, customer churn and delayed healthcare deliveries; adjusted EBITA returned to positive territory QoQ.

  • Priorities shifted toward recurring gross profit and cash, supported by cost reductions, a leaner organisation and shared operating platforms.

  • Commercial opportunities include Sweden’s largest contract to date, Samsung Knox Premium MSP status and a German software project, with delivery and conversion to recurring gross profit still key.

Financial highlights

  • Q3 revenue was NOK 168.957m, down 7% YoY excluding the divested business and down 24% on a reported basis.

  • Net gross profit was NOK 53.421m, down 13% excluding the divested business and down 34% on a reported basis; margin was 31.6% versus 33.7%.

  • Adjusted EBITA was NOK 2.109m versus NOK 5.405m YoY and improved NOK 15m QoQ from -NOK 12.9m; operating costs fell NOK 4.9m YoY.

  • Net loss was NOK 151.421m, including NOK 137.1m non-cash goodwill impairment; amortisation was NOK 8.0m versus NOK 17.5m YoY.

  • Adjusted EBITDA was NOK 24.148m; operating cash flow was -NOK 20.0m after DaaS investment.

Outlook and guidance

  • Annualised operating cost-base target is NOK 218m, with close to full Improvement Programme effect expected by April 2027; September costs reached the target run-rate, partly aided by vacation effects and temporarily lower costs.

  • Q4 priorities are to grow gross profit from existing customers, selectively win profitable new work and lower costs; progress measures include delivery, recurring gross profit and cash.

  • Partner-channel ambition is ~40% of gross profit by 2029, a directional target rather than financial guidance, subject to execution, partner adoption and market development.

  • Healthcare rollout under the Sykehuspartner agreement is delayed but expected to gain momentum; timing, retention and long sales and delivery cycles remain execution risks.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Techstep